150 related articles for article (PubMed ID: 2467912)
1. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.
Salonen EM; Vaheri A; Pöllänen J; Stephens R; Andreasen P; Mayer M; Danø K; Gailit J; Ruoslahti E
J Biol Chem; 1989 Apr; 264(11):6339-43. PubMed ID: 2467912
[TBL] [Abstract][Full Text] [Related]
2. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
Sakata Y; Okada M; Noro A; Matsuda M
J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
[TBL] [Abstract][Full Text] [Related]
3. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue.
Kirchheimer JC; Binder BR; Remold HG
J Immunol; 1990 Sep; 145(5):1518-22. PubMed ID: 1696600
[TBL] [Abstract][Full Text] [Related]
4. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1.
Manchanda N; Schwartz BS
J Biol Chem; 1995 Aug; 270(34):20032-5. PubMed ID: 7544349
[TBL] [Abstract][Full Text] [Related]
5. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
6. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
Wun TC; Palmier MO; Siegel NR; Smith CE
J Biol Chem; 1989 May; 264(14):7862-8. PubMed ID: 2470735
[TBL] [Abstract][Full Text] [Related]
7. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
8. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
11. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
12. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
[TBL] [Abstract][Full Text] [Related]
13. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
14. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
[TBL] [Abstract][Full Text] [Related]
15. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors.
Kirchheimer JC; Remold HG
Blood; 1989 Sep; 74(4):1396-402. PubMed ID: 2548640
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin.
Seiffert D; Loskutoff DJ
Biochim Biophys Acta; 1991 May; 1078(1):23-30. PubMed ID: 1710930
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
Declerck PJ; De Mol M; Alessi MC; Baudner S; Pâques EP; Preissner KT; Müller-Berghaus G; Collen D
J Biol Chem; 1988 Oct; 263(30):15454-61. PubMed ID: 2459123
[TBL] [Abstract][Full Text] [Related]
18. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
19. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
Edelberg JM; Reilly CF; Pizzo SV
J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
[TBL] [Abstract][Full Text] [Related]
20. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
